{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:43:12Z","timestamp":1787838192924,"version":"build-2784847793"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>In the INFORM-1 study, 73 patients with chronic hepatitis C virus infection received mericitabine plus danoprevir for up to 13 days. Seventy-two patients experienced a continuous decline in HCV RNA levels during treatment, and of these patients, 14 had viral loads that remained &gt;1,000 IU\/ml by day 13 and 1 met the definition for viral breakthrough. In-depth NS5B and NS3\/4A population and clonal sequencing studies and mericitabine and danoprevir drug susceptibility testing were performed to assess the variability and quasispecies dynamics before and upon monotherapy or dual therapy. Sequence analysis of the viral quasispecies indicated that the mericitabine resistance mutation S282T was not present at baseline, nor was it selected (even at a low level) during treatment. Protease inhibitor resistance mutations, either as predominant or as minority species, were detected in 18 patients at baseline. No enrichment of minority protease inhibitor-resistant variants present at baseline was observed during treatment; viral population samples were fully susceptible to mericitabine and\/or danoprevir, despite the presence within their quasispecies of minority variants confirmed to have reduced susceptibility to danoprevir or other protease inhibitors. It was also observed that certain NS3 amino acid substitutions affected protease inhibitor drug susceptibility in a compound-specific manner and varied with the genetic context. In summary, the slower kinetics of viral load decline observed in some patients was not due to the selection of danoprevir or mericitabine resistance during treatment. Over 2 weeks' therapy, mericitabine suppressed the selection of danoprevir resistance, results that could differ upon longer treatment periods.<\/jats:p>","DOI":"10.1128\/aac.01035-12","type":"journal-article","created":{"date-parts":[[2012,8,7]],"date-time":"2012-08-07T02:49:14Z","timestamp":1344307754000},"page":"5494-5502","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["Characterization of Hepatitis C Virus (HCV) Quasispecies Dynamics upon Short-Term Dual Therapy with the HCV NS5B Nucleoside Polymerase Inhibitor Mericitabine and the NS3\/4 Protease Inhibitor Danoprevir"],"prefix":"10.1128","volume":"56","author":[{"given":"S.","family":"Le Pogam","sequence":"first","affiliation":[{"name":"Roche, Nutley, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Yan","sequence":"additional","affiliation":[{"name":"Roche, Nutley, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chhabra","sequence":"additional","affiliation":[{"name":"Roche, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ilnicka","sequence":"additional","affiliation":[{"name":"Roche, Nutley, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kang","sequence":"additional","affiliation":[{"name":"Roche, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kosaka","sequence":"additional","affiliation":[{"name":"Roche, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ali","sequence":"additional","affiliation":[{"name":"Roche, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Chin","sequence":"additional","affiliation":[{"name":"Roche, Nutley, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. S.","family":"Shulman","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Smith","sequence":"additional","affiliation":[{"name":"Roche, Nutley, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Klumpp","sequence":"additional","affiliation":[{"name":"Roche, Nutley, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"N\u00e1jera","sequence":"additional","affiliation":[{"name":"Roche, Nutley, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00444-08"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24724"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jhep.2010.11.001","article-title":"Treatment of chronic hepatitis C patients with the NS3\/4A protease inhibitor danoprevir (ITMN-191\/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study","volume":"54","author":"Forestier N","year":"2011","unstructured":"ForestierN. 2011. Treatment of chronic hepatitis C patients with the NS3\/4A protease inhibitor danoprevir (ITMN-191\/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J. Hepatol. 54:1130\u20131136.","journal-title":"J. Hepatol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/infdis\/jir315","article-title":"Antiviral activity of danoprevir (ITMN-191\/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C","volume":"204","author":"Forestier N","year":"2011","unstructured":"ForestierN. 2011. Antiviral activity of danoprevir (ITMN-191\/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C. J. Infect. Dis. 204:601\u2013608.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.21774","article-title":"Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C","volume":"46","author":"Forestier N","year":"2007","unstructured":"ForestierN. 2007. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46:640\u2013648.","journal-title":"Hepatology"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.1016\/S0168-8278(12)61423-8","article-title":"Interferon-free treatment with a combination of mericitabine and danoprevir\/r with or without ribavirin in treatment-naive HCV genotype-1 infected patients","volume":"56","author":"Gane EJ","year":"2012","unstructured":"GaneEJ. 2012. Interferon-free treatment with a combination of mericitabine and danoprevir\/r with or without ribavirin in treatment-naive HCV genotype-1 infected patients. J. Hepatol. 56(Suppl S2):S555\u2013S556.","journal-title":"J. Hepatol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61384-0"},{"key":"e_1_3_2_9_2","unstructured":"GaneEJ. 2011. Once daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients HCV GT2 or GT3 abstr 34. 54(Suppl):377A."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22773"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24641"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_3_2_13_2","first-page":"360A","article-title":"High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1\/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)\/RBV: planned week 12 interim analysis from the PROPEL study","volume":"52","author":"Jensen DM","year":"2010","unstructured":"JensenDM. 2010. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1\/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)\/RBV: planned week 12 interim analysis from the PROPEL study. Hepatology 52(Suppl 1):360A.","journal-title":"Hepatology"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21781"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22549"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60934-8"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.03.027"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1016\/S0168-8278(11)61223-3","article-title":"Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PEG\/IFN alpha-2a\/ribavirin","volume":"54","author":"Lenz O","year":"2011","unstructured":"LenzO. 2011. Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PEG\/IFN alpha-2a\/ribavirin. J. Hepatol. 54(Suppl 1):S482\u2013S483.","journal-title":"J. Hepatol."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01452-09"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/656774"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn085"},{"key":"e_1_3_2_22_2","first-page":"701","article-title":"No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN-\/RBV combination treatment for up to 12 weeks: interim analysis from the PROPEL study","volume":"52","author":"Le Pogam S","year":"2010","unstructured":"Le PogamS. 2010. No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN-\/RBV combination treatment for up to 12 weeks: interim analysis from the PROPEL study. Hepatology 52(Suppl 1):701\u2013702A.","journal-title":"Hepatology"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05636-11"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104430"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M705274200"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1016\/S0168-8278(09)60962-4","article-title":"Suppression of in vitro resistance development after treatment of the HCV replicon with NS3\/4a inhibitor ITMN-191 (R7227) in combination with nucleoside inhibitor R7128 or R1626","volume":"50","author":"McCown M","year":"2009","unstructured":"McCownM RajyaguruS KularS CammackN NajeraI. 2009. Suppression of in vitro resistance development after treatment of the HCV replicon with NS3\/4a inhibitor ITMN-191 (R7227) in combination with nucleoside inhibitor R7128 or R1626. J. Hepatol. 50(Suppl 1):S349.","journal-title":"J. Hepatol."},{"key":"e_1_3_2_27_2","unstructured":"Merck & Co. Inc. 2011. Victrelis (boceprevir) prescribing information. Merck & Co. Inc. Whitehouse Station NJ.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202258lbl.pdf."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M305041200"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24262"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1016\/S0168-8278(11)61361-5","article-title":"First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon\/ribavirin in treatment-naive HCV G1\/4 patients: interim analysis from the JUMP-C trial","volume":"54","author":"Pockros P","year":"2011","unstructured":"PockrosP. 2011. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon\/ribavirin in treatment-naive HCV G1\/4 patients: interim analysis from the JUMP-C trial. J. Hepatol. 54:S538.","journal-title":"J. Hepatol."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_3_2_32_2","first-page":"1024A","article-title":"Antiviral activity and safety of TMC435 combined with pegylated interferon and ribavirin in hepatitis C patients with genotype 1 who had previous exposure to TMC435","volume":"50","author":"Reesink H","year":"2009","unstructured":"ReesinkH. 2009. Antiviral activity and safety of TMC435 combined with pegylated interferon and ribavirin in hepatitis C patients with genotype 1 who had previous exposure to TMC435. Hepatology 50(Suppl):1024A.","journal-title":"Hepatology"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study","volume":"131","author":"Reesink HW","year":"2006","unstructured":"ReesinkHW. 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131:997\u20131002.","journal-title":"Gastroenterology"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000544"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.02.037"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/j.gastro.2007.01.041","article-title":"SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders","volume":"132","author":"Sarrazin C","year":"2007","unstructured":"SarrazinC. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132:1270\u20131278.","journal-title":"Gastroenterology"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1016\/S0168-8278(07)62245-4","article-title":"Sequence variation of NS3\/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those likely to be achieved following clinical dosing","volume":"46","author":"Seiwert S","unstructured":"SeiwertS. Sequence variation of NS3\/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those likely to be achieved following clinical dosing. J. Hepatol. 46(Suppl 1):S244\u2013S245.","journal-title":"J. Hepatol."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020601700203"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23192"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1760"},{"key":"e_1_3_2_41_2","first-page":"89","article-title":"High genetic barrier to HCV resistance presented by PSI-6130, abstr 83","volume":"3","author":"Uzgiris A","unstructured":"UzgirisA. High genetic barrier to HCV resistance presented by PSI-6130, abstr 83. Global Antiviral J. 3(Suppl 2):89.","journal-title":"Global Antiviral J."},{"key":"e_1_3_2_42_2","unstructured":"Vertex Pharmaceuticals Ltd. 2011. Incivek (telaprevir) prescribing information. Vertex Pharmaceuticals Ltd. Cambridge MA. http:\/\/www.Natap.org\/2011\/HCV\/INCIVEKUSPI.pdf."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00863-07"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01035-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01035-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:56:22Z","timestamp":1645480582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01035-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1128\/AAC.01035-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01035-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"2012-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}